 SANTA MONICA, Calif., Aug. 08, 2021 GLOBE NEWSWIRE -- BioVie Inc., NASDAQ: BIVI BioVie or the Company a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced the pricing of its underwritten public offering of 2,500,000 shares of its Class A common stock at a public offering price of 8.00 per share, for gross proceeds of 20,000,000, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45 day option to purchase up to an additional 375,000 shares of common stock to cover over-allotments at the offering price, less the underwriting discount. 